Vivos (RDGL) Net Income towards Common Stockholders (2010 - 2025)
Vivos' (RDGL) quarterly Net Income towards Common Stockholders came in at -$1.1 million in Q4 2025, down 5.41% year-on-year from -$1.1 million in Q4 2024, and down 112.6% quarter-over-quarter from -$507294.0 in Q3 2025.
Vivos (RDGL) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Vivos has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting -$1.1 million for Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$1.1 million, down 5.41% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.1 million (down 5.35% YoY), and the FY2025 annual result was -$3.1 million, down 5.35% from the prior year.
- Net Income towards Common Stockholders came in at -$1.1 million for Q4 2025 at Vivos, down from -$507294.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$178230.0 in Q4 2021 to a low of -$1.9 million in Q2 2021.
- The 5-year median for Net Income towards Common Stockholders is -$683797.5 (2022), against an average of -$693457.2.
- Across the five-year window, Net Income towards Common Stockholders tumbled 1069.29% in 2021 and jumped 64.52% in 2023, its largest moves.
- Vivos' Net Income towards Common Stockholders stood at -$178230.0 in 2021, then tumbled by 295.92% to -$705653.0 in 2022, then sank by 52.51% to -$1.1 million in 2023, then grew by 4.93% to -$1.0 million in 2024, then retreated by 5.41% to -$1.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$1.1 million (Q4 2025), -$507294.0 (Q3 2025), and -$645513.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Vivos | - | - | -3,105.00 | -1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -507,294.00 |
| Jun 30, 2025 | -645,513.00 |
| Mar 31, 2025 | -834,696.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -825,263.00 |
| Jun 30, 2024 | -503,458.00 |
| Mar 31, 2024 | -558,539.00 |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -667,690.00 |
| Jun 30, 2023 | -902,526.00 |
| Mar 31, 2023 | -248,318.00 |
| Dec 31, 2022 | -705,653.00 |
| Sep 30, 2022 | -277,065.00 |
| Jun 30, 2022 | -787,538.00 |
| Mar 31, 2022 | -699,905.00 |
| Dec 31, 2021 | -178,230.00 |
| Sep 30, 2021 | -201,160.00 |
| Jun 30, 2021 | -1.86 Mn |
| Mar 31, 2021 | -288,189.00 |